幽门螺杆菌
微生物学
失调
肠道菌群
粪便
厚壁菌
放线菌门
胃炎
医学
内科学
胃肠病学
螺杆菌
克拉霉素
幽门螺杆菌感染
抗生素
抗生素耐药性
质子抑制剂泵
阿莫西林
生物
细菌
免疫学
16S核糖体RNA
遗传学
作者
Ping-I Hsu,Chao-Yu Pan,John Y. Kao,Feng-Woei Tsay,Nan-Jing Peng,Sung-Shuo Kao,Yan-Hua Chen,Tzung-Jiun Tsai,Deng-Chyang Wu,Kuo-Wang Tsai
摘要
Anti-Helicobacter pylori therapy may lead to the growth of pathogenic or antibiotic-resistant bacteria in the gut. The study aimed to investigate the short-term and long-term impacts of H. pylori eradication with reverse hybrid therapy on the components and macrolide resistance of the gut microbiota.Helicobacter pylori-related gastritis patients were administered a 14-day reverse hybrid therapy. Fecal samples were collected before treatment and at the end of week 2, week 8, and week 48. The V3-V4 region of the bacterial 16S rRNA gene in fecal specimens was amplified by polymerase chain reaction and sequenced on Illumina MiSeq platform. Additionally, amplification of erm(B) gene (encoding erythromycin resistance methylase) was performed.Reverse hybrid therapy resulted in decreased relative abundances of Firmicutes (from 62.0% to 30.7%; P < 0.001) and Actinobacteria (from 3.4% to 0.6%; 0.032) at the end of therapy. In contrast, the relative abundance of Proteobacteria increased from 10.2% to 49.1% (0.002). These microbiota alterations did not persist but returned to the initial levels at week 8 and week 48. The amount of erm(B) gene in fecal specimens was comparable with the pretreatment level at week 2 but increased at week 8 (0.025) and then returned to the pretreatment level by week 48.Helicobacter pylori eradication with reverse hybrid therapy can lead to short-term gut dysbiosis. The amount of erm(B) gene in the stool increased transiently after treatment and returned to the pretreatment level at 1-year post-treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI